blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
Published 2 years ago • 189 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
3:26
blc2001: erdafitinib for muc
-
2:31
an update on erdafitinib for metastatic/uresectable fgfr alteration urothelial carcinoma
-
1:28
erdafitinib for bladder cancer: more to come following fda approval
-
0:49
evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
-
4:43
erdafitinib for fgfr-mutated urothelial carcinoma
-
1:15
what role will erdafitinib play in treating metastatic urothelial carcinoma?
-
1:23
recent advances in the use of targeted therapies for metastatic urothelial carcinoma
-
3:37
optimal treatment strategies for patients with metastatic urothelial carcinoma
-
2:05
the evolving treatment landscape of advanced and metastatic urothelial carcinoma
-
1:09
futibatinib plus pembrolizumab for the treatment of advanced or metastatic urothelial carcinoma
-
1:17
recent treatment approvals for metastatic and advanced urothelial carcinoma
-
2:20
the role of erdafitinib in treating patients with bladder cancer
-
1:04
thor: erdafitinib in advanced or metastatic urothelial cancer and fgfr alterations
-
2:12
erdafitinib: one more tool for bladder cancer
-
2:02
the evolving treatment landscape for urothelial cancer
-
0:58
replacing the current standard of care for urothelial carcinoma
-
2:20
erdafitinib /- cetrelimab in muc patients with fgfr alterations
-
3:42
norse: erdafitinib cetrelimab in muc with fgfr alterations
-
1:27
erdafitinib and enfortumab vedotin in pretreated fgfr2/3-mutant bladder cancer